Patents by Inventor Astrid Kiermaier

Astrid Kiermaier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDENTIFICATION OF NON-RESPONDERS TO HER2 INHIBITORS
    Publication number: 20160265067
    Abstract: The present invention relates to means and methods for the identification of non-responders to a HER2 inhibitor, whereby one or more mutations in exon 9 of Phosphoinositol-3 kinase (PIK3CA) indicate non-responsiveness.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Inventors: Victoria Brophy, Neil Jones, Astrid Kiermaier, Jayantha Ratnayake
  • Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
    Patent number: 9376715
    Abstract: The present invention relates to means and methods for the identification of non-responders to a HER2 inhibitor, whereby one or more mutations in exon 9 of Phosphoinositol-3 kinase (PIK3CA) indicate non-responsiveness.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: June 28, 2016
    Assignee: ROCHE MOLECULAR SYSTEMS, INC
    Inventors: Victoria Brophy, Neil Jones, Astrid Kiermaier, Jayantha Ratnayake
  • IDENTIFICATION OF NON-RESPONDERS TO HER2 INHIBITORS
    Publication number: 20150079076
    Abstract: The present invention relates to means and methods for the identification of non-responders to a HER2 inhibitor, whereby one or more mutations in exon 9 of Phosphoinositol-3 kinase (PIK3CA) indicate non-responsiveness.
    Type: Application
    Filed: December 7, 2012
    Publication date: March 19, 2015
    Applicant: ROCHE MOLECULAR SYSTEMS
    Inventors: Victoria Brophy, Neil Jones, Astrid Kiermaier, Jayantha Ratnayake
  • MODULATORS FOR HER2 SIGNALING IN HER2 EXPRESSING PATIENTS WITH GASTRIC CANCER
    Publication number: 20120121586
    Abstract: The present invention relates to means and methods for the identification of responders for or a patient sensitive to a modulator of the HER2/neu (ErbB2) signaling pathway. Also described herein are corresponding methods of treatment of a group of patients determined and defined in accordance with the identification method of the present invention, whereby said group of patients is known or suspected to suffer from or being prone to suffer from gastric cancer in particular invasive gastric cancer.
    Type: Application
    Filed: May 28, 2010
    Publication date: May 17, 2012
    Inventors: Astrid Kiermaier, Marlene Pickl, Josef Rueschoff